Combination contraceptive effects on monthly cycle of plasma aldosterone, renin activity and renin substrate.
A post-ovulatory peak of fasting supine plasma aldosterone (PA) preceded or accompanied by an increase in plasma renin activity (PRA) was previously reported. These studies have now been extended in 4 additional normal menstruating women and 4 women taking oestrogen-progestogen oral contraceptive pills (OCP), all studied daily for an entire cycle. Distinct luteal phase increases in PRA were seen in the 4 normals, with 2 also demonstrating a rise in PA. Plasma renin substrate (PRS) was usually unvarying throughout the control cycles. The women taking OCP, on the other hand, all had PA and PRA peaks that were apparent by the fourth or fifth day of taking "the pill". All 4 of the treated women had elevated PRS levels but only one woman showed an increase which preceded the elevation of PRA and PA. Plasma cortisol levels were usually above the normal range in the women taking OCP. This study thus indicates that factors other than oestrogen-induced increased substrate production may be responsible for the PRA and PA rise during OCP treatment. Such factors might be the natri-uretic effects of oestrogens and progestogens or a direct effect on renin secretion by one of these steroids.
D000328:Adult; D000450:Aldosterone / Q000097:blood*; D003276:Contraceptives, Oral / Q000494:pharmacology*; D003278:Contraceptives, Oral, Hormonal / Q000494:pharmacology*; D003338:Corpus Luteum; D005260:Female; D006801:Humans; D006854:Hydrocortisone / Q000097:blood; D008598:Menstruation; D010060:Ovulation; D012083:Renin / Q000097:blood*; D013268:Stimulation, Chemical; D013997:Time Factors
D003276:Contraceptives, Oral; D003278:Contraceptives, Oral, Hormonal; D000450:Aldosterone; D012083:Renin; D006854:Hydrocortisone